All News

2017

June

Media Release / Jun 19, 2017

Sandoz receives approval in Europe for Rixathon® (biosimilar rituximab) to treat blood cancers and immunological diseases

Read More
Media Release / Jun 13, 2017

US Supreme Court rules in favor of Sandoz in biosimilars case, enabling earlier access to potentially life-saving medicines

Read More

May

Media Release / May 31, 2017

Sandoz proposed biosimilars adalimumab and infliximab accepted for regulatory review by the European Medicines Agency

Read More
Media Release / May 02, 2017

Sandoz Canada launches PrSandoz® Olmesartan for the treatment of high blood pressure

Read More

April

Media Release / Apr 28, 2017

Community Partnership Day

Read More
Media Release / Apr 21, 2017

Sandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe*

Read More
Media Release / Apr 18, 2017

Sandoz Canada launches Mosaspray™ in Québec: a non-prescription mometasone nasal spray for the treatment of the symptoms of allergic rhinitis

Read More

March

Media Release / Mar 06, 2017

New data demonstrate Sandoz proposed biosimilar adalimumab has equivalent efficacy to reference medicine

Read More

January

Media Release / Jan 31, 2017

Sandoz Canada launches Sandoz® Amphetamine XR for the treatment of Attention Deficit Hyperactivity Disorder (ADHD)

Read More
2016

July

Media Release / Jul 07, 2016

New data shows Sandoz biosimilar etanercept candidate has equivalent efficacy to originator product

Read More

Pages